Skip to main content
Sign In
 

Newsroom

Highlights from the Blood Cancer and BMT Program


2018 Division of Hematology Awards

​​​​​We proudly honor the following individuals who were presented with Division of Hematology awards in 2018.

New Drug trial at CU Anschutz may be a cure to a strain of Leukemia

9 News. A new treatment (Venetoclax + Azacitidine) appears to be more aggressive than the cancer it treats.

UCHealth brings back 'Hit the Mitt' for cancer research at Coors Field

9 News. For the second year in a row, UCHealth is doing their "Hit the Mitt" campaign - if a player hits a banner in the stands of Coors Field with a home run, UCHealth donates $5,000 to a leukemia and lymphoma society.

This CU Drug Trial May Be A Cure For An Aggressive Strain Of Leukemia

Colorado Public Radio covers a CU trial drug, venetoclax, which is producing a 91 percent response rate in Acute Myeloid Leukemia (AML).

Getting to the Root of Leukemia

Chemotherapy and bone marrow transplant are the standard-of-care for AML. Now the basic science from Jordan’s lab and the results from clinical trials in Pollyea’s and Smith’s patients are leading to a new paradigm for the treatment of AML.

Pollyea and Pietras earn endowed chairs

Cancer Center announces two newly endowed chairs: Daniel Pollyea, MD, recipient of the Robert H. Allen Endowed Chair in Hematology Research, and Eric Pietras, PhD, recipient of the Ceo Meador/George Ryland Scott Endowed Chair in Hematology Research.

91 percent response rate for venetoclax

Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML).

Cancer hijacks the microbiome to glut itself on glucose

Cancer gets energy in the form of glucose. But how does it get this glucose? A recent study shows that leukemia undercuts the ability of normal cells to consume glucose, leaving more glucose available to feed its own growth.

Angelo D'Alessandro to become NBF Scholar

Angelo D’Alessandro, PhD, will be honored by receiving the title of National Blood Foundation Scholar next month for completing a study funded by an NBF early-career Scientific Research Grant in 2016.

Patients light the night to support blood cancer cures

Nathan Kissack figured he pulled a muscle while cutting hay for the cows on his ranch. Worried about his back, Kissack went to see a buddy who’s a chiropractor. The news was bad. An X-ray showed a large tumor right in the middle of Kissack’s chest.

UCHealth providers join forces to battle an elusive cancer foe

The multidisciplinary clinic targets cutaneous lymphoma, a difficult-to-diagnose cancer that attacks white blood cells and arises in the skin.

CAR-T immunotherapy at UCHealth brings ‘new lease on life’

In one of the most exciting developments in the fight against cancer, CAR-T immunotherapy delivers a remarkable respite from blood cancer.

Lindsey Lyle and Alex Hirose Publication--Iron Overload in Myelodysplastic Syndromes

LINDSEY LYLE, MS, PA-C, and ALEX HIROSE, MMS, PA-C publish​ Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment

Blood Disorders Center APPs Featured on SOM Site

Nurse practitioners (NP) and physician assistants (PA) are an integral part of the BDC healthcare team caring for patients in the hospital, clinics and procedural settings.

Managing Adverse Events

Dwight C. Macero, MS, PA-C, discusses the role that advanced practice providers play in managing the side effects of hematologic treatments.